Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Growing
The company is in a growing phase, with the latest annual income totaling USD 858.00K.
Undervalued
The company’s latest PE is -11.60, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.48M shares, decreasing 10.59% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 323.47K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.90.